Cohort 1

DRUG10 trials

Sponsors

Protagonist Therapeutics Inc, Brown University, Cougar Biotechnology, Inc., National Cancer Institute (NCI), Janssen Research & Development, LLC

Conditions

Anaplastic AstrocytomaAstrocytic TumorsB Cell LeukemiasB Cell LymphomasBrain TumorChronic anemia due to ineffective erythropoiesis (IE) in subjects with ß thalassemia ThalassemiaCongenital HyperinsulinismGlioblastoma Multiforme

Phase 1

A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema

CompletedNCT00439179

Brown UniversityMetastatic Pancreatic Cancer

Start: 2006-07-31End: 2007-12-31Updated: 2020-02-17

A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

CompletedNCT01400555

Cougar Biotechnology, Inc.Prostate Cancer, Prostate Neoplasms

Start: 2011-09-01End: 2017-02-28Updated: 2018-03-21

A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function

CompletedNCT01516047

Janssen Research & Development, LLCHepatic Impairment

Start: 2012-01-31End: 2012-09-30Updated: 2014-06-25

Phase I Study of Safety and Immunogenicity of ADU-623

CompletedNCT01967758

Providence Health & ServicesAnaplastic Astrocytoma, Astrocytic Tumors, Brain Tumor +1

Start: 2014-01-08End: 2018-08-15Updated: 2018-08-17

CD22 Redirected Autologous T Cells for ALL

Active, not recruitingNCT02650414

University of PennsylvaniaB Cell Leukemias, B Cell Lymphomas

Start: 2016-01-13End: 2037-12-01Target: 41Updated: 2026-07-07

Phase 2

Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

RecruitingNCT01419561

National Cancer Institute (NCI)HHV-8, KSHV, KSHV Inflammatory Cytokine Syndrome (KICS)

Start: 2011-09-08End: 2028-12-31Target: 140Updated: 2026-09-08

A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism

CompletedNCT02604485

XOMA (US) LLCCongenital Hyperinsulinism

Start: 2015-10-31End: 2017-01-31Updated: 2017-02-06

A Phase 2 Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) ß-Thalassemia Subjects with Chronic Anemia

Active, not recruitingLBCTR2019020179

Protagonist Therapeutics IncChronic anemia due to ineffective erythropoiesis (IE) in subjects with ß thalassemia Thalassemia

Start: 2019-03-11Target: 84Updated: 2026-02-02

Unknown Phase

Long-Term Clinical, Immunologic, and Virologic Profiles of Children Who Received Early Treatment for HIV

CompletedNCT05154513

International Maternal Pediatric Adolescent AIDS Clinical Trials GroupHIV Infection

Start: 2022-02-02End: 2025-07-30Updated: 2026-01-13

Identification and Description of Patients With High-risk Non Metastatic RCC

RecruitingNCT07753343

University Hospital, BordeauxRenal Cell Carcinoma

Start: 2026-04-17End: 2028-04-17Target: 6109Updated: 2026-08-07

Related Papers

Distinct immune profiles among patients with primary effusion lymphoma and other kaposi sarcoma herpesvirus-associated diseases

Blood2025-11-03

Characteristics and outcomes of Kaposi sarcoma herpesvirus-associated inflammatory cytokine syndrome.

2025-11-013 citations

CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy

Journal for ImmunoTherapy of Cancer2025-04-019 citations

Abstract B051: Marrow and peripheral blood cytokine architecture differences between pediatric patients receiving CD19- and CD22-directed CART

Cancer Research2024-09-05

Inflammasome activation in patients with Kaposi sarcoma herpesvirus–associated diseases

Blood2024-06-2816 citations

IL-10 Levels Differentially Regulate IFNg Signaling of CART19 and CART22

Blood2023-11-02

CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Blood2022-11-156 citations

Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.

2021-04-22148 citations

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

Blood2019-11-1317 citations

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

Blood2017-12-076 citations

Phase I study of safety and immunogenicity of ADU-623, a live-attenuated <i>Listeria monocytogenes </i>vaccine (Δ<i>actA</i>/Δ<i>inlB</i>) expressing EGFRvIII and NY-ESO-1, in patients with WHO grade III/IV astrocytomas.

Journal of Clinical Oncology2015-05-201 citations

Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2014-05-202 citations

Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2014-02-011 citations